Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be Presented at Annual Meeting of American Society of Clinical Oncology

ARIAD Pharmaceuticals, 05/17/2012

ARIAD Pharmaceuticals, Inc. announced that updated clinical data from the pivotal PACE trial of its investigational, pan–BCR–ABL inhibitor, ponatinib, will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, June 2012.

Print Article Summary